The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a new study suggests, based on results from the phase-2 clinical trial, known as the CLEAR-ER Stroke Trial.